GlaxoSmithKline

August 6, 2001

Dear Mr. Yamada:

As over 8 months have past since the removal of
Lotronex from the market, all but a handful of people
taking the medicine have run out leaving them with no
effective alternative treatment.  The fact that no
effective alternative treatment exists is undisputable
and has been stated publicly by Dr. Palmer:

"We greatly regret this outcome and believe that
Lotronex is effective, that its side effects are
manageable, and that the benefits of the product when
treating IBS outweigh the risks," said Dr James
Palmer, Senior Vice President and Director Group
Medical, Regulatory and Product Strategy, Glaxo
Wellcome plc. "Thousands of women who have benefited
from Lotronex will have to resort to therapies which
did not adequately treat their symptoms in the past."

While the Lotronex Action Group understands that
discussions for "continued marketing" of the medicine
are currently taking place, the simple fact remains
that those in need of the medicine do not have access
to it, thus, causing undue suffering for those with
the most severe form of IBS-D.  GSK can blame FDA and
FDA can blame GSK for eternity, but both are to blame
for the pain and suffering of thousands of people that
need the medicine.  Moreover, both are to blame for
the continued delay to the resolution of this issue.

GSK has proven through its actions, that the patients
come last in this issue.  This cannot be disputed as
GSK could release the medicine unders many forms of
IND, but chooses not to.   

GSK could also sell the medicine in Mexico according
to an early press story regarding locations where the
medicine has been approved for sale:

"Lotronex is also approved but not yet marketed in
Mexico, Argentina, Brazil and South Korea and there
are over 30 regulatory submissions pending around the
world."

Either providing the medicine under an IND or selling
it in Mexico would allow those who suffer the most
severe form of the illness opportunity for access.

If corporate profits and stock holders are the primary
concern of your company, than GSK should get out of
the pharmaceutical business.  If providing effective
treatments to those that suffer from debilitating
illnesses, such as severe IBS-D, is of importance to
your company, than all we can tell you is that the
actions of GSK do not show this.

We have asked for your compassion, many have begged
and pleaded to you, and it is time for GSK to step up
to the plate and help those in need.  Your
competitors, Solvay and Novartis, have reacted with
much more force and cooperation with the FDA on the
issues of both Cilansetron and Zelnorm. Why will GSK
not do the same?

Once again, we ask for your compassion and allow
Lotronex to be made available under an IND while
continued discussions occur for long-term marketing.

Sincerely,

Corey Miller, Coordinator
Lotronex Action group